129 related articles for article (PubMed ID: 23562876)
1. A phenotypic screening assay for modulators of huntingtin-induced transcriptional dysregulation.
Lazzeroni G; Benicchi T; Heitz F; Magnoni L; Diamanti D; Rossini L; Massai L; Federico C; Fecke W; Caricasole A; La Rosa S; Porcari V
J Biomol Screen; 2013 Oct; 18(9):984-96. PubMed ID: 23562876
[TBL] [Abstract][Full Text] [Related]
2. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
Bates EA; Victor M; Jones AK; Shi Y; Hart AC
J Neurosci; 2006 Mar; 26(10):2830-8. PubMed ID: 16525063
[TBL] [Abstract][Full Text] [Related]
3. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.
Jiang H; Poirier MA; Liang Y; Pei Z; Weiskittel CE; Smith WW; DeFranco DB; Ross CA
Neurobiol Dis; 2006 Sep; 23(3):543-51. PubMed ID: 16766198
[TBL] [Abstract][Full Text] [Related]
4. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
[TBL] [Abstract][Full Text] [Related]
5. Small molecule drug discovery for Huntington's Disease.
Fecke W; Gianfriddo M; Gaviraghi G; Terstappen GC; Heitz F
Drug Discov Today; 2009 May; 14(9-10):453-64. PubMed ID: 19429504
[TBL] [Abstract][Full Text] [Related]
6. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis.
Sugars KL; Brown R; Cook LJ; Swartz J; Rubinsztein DC
J Biol Chem; 2004 Feb; 279(6):4988-99. PubMed ID: 14627700
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a potent small molecule inhibiting Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein.
Khan E; Mishra SK; Mishra R; Mishra A; Kumar A
Sci Rep; 2019 Nov; 9(1):16872. PubMed ID: 31728006
[TBL] [Abstract][Full Text] [Related]
8. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.
Nucifora FC; Sasaki M; Peters MF; Huang H; Cooper JK; Yamada M; Takahashi H; Tsuji S; Troncoso J; Dawson VL; Dawson TM; Ross CA
Science; 2001 Mar; 291(5512):2423-8. PubMed ID: 11264541
[TBL] [Abstract][Full Text] [Related]
9. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
Truant R; Atwal RS; Burtnik A
Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
[TBL] [Abstract][Full Text] [Related]
10. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.
Charvin D; Vanhoutte P; Pagès C; Borrelli E; Caboche J
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12218-23. PubMed ID: 16103364
[TBL] [Abstract][Full Text] [Related]
11. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract.
Hazeki N; Nakamura K; Goto J; Kanazawa I
Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
[TBL] [Abstract][Full Text] [Related]
13. A huntingtin peptide inhibits polyQ-huntingtin associated defects.
Arribat Y; Bonneaud N; Talmat-Amar Y; Layalle S; Parmentier ML; Maschat F
PLoS One; 2013; 8(7):e68775. PubMed ID: 23861941
[TBL] [Abstract][Full Text] [Related]
14. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
[TBL] [Abstract][Full Text] [Related]
15. Suppression of aggregate formation of mutant huntingtin potentiates CREB-binding protein sequestration and apoptotic cell death.
Choi YJ; Kim SI; Lee JW; Kwon YS; Lee HJ; Kim SS; Chun W
Mol Cell Neurosci; 2012 Feb; 49(2):127-37. PubMed ID: 22122824
[TBL] [Abstract][Full Text] [Related]
16. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death.
Roze E; Betuing S; Deyts C; Marcon E; Brami-Cherrier K; Pagès C; Humbert S; Mérienne K; Caboche J
FASEB J; 2008 Apr; 22(4):1083-93. PubMed ID: 18029446
[TBL] [Abstract][Full Text] [Related]
17. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
[TBL] [Abstract][Full Text] [Related]
18. Toll-interacting protein pathway: degradation of an ubiquitin-binding protein.
Shimizu M; Oguro-Ando A; Ohoto-Fujita E; Atomi Y
Methods Enzymol; 2014; 534():323-30. PubMed ID: 24359962
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.
Bithell A; Johnson R; Buckley NJ
Biochem Soc Trans; 2009 Dec; 37(Pt 6):1270-5. PubMed ID: 19909260
[TBL] [Abstract][Full Text] [Related]
20. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
